Beijing Chunlizhengda Medical Instruments (HKG:1858, SHA:688236) expects an attributable profit of between around 107.8 million yuan and 127.8 million yuan for the year 2024, down 54% to 61% from 277.8 million yuan, a year prior, a Friday bourse filing said.
The orthopedic medical device company attributed the lower anticipated profit mainly to a decline in revenue and net profit amid the continuous deepening of its centralized procurement policy leading to lower product prices and adjustments to the price of channel inventory.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。